Patents by Inventor Marcos GONZALEZ-LOPEZ

Marcos GONZALEZ-LOPEZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic pyridones and pyrimidones
    Patent number: 11845761
    Abstract: Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: December 19, 2023
    Assignee: Erasca, Inc.
    Inventors: Jun Feng, Jean-Michel Vernier, Marcos Gonzalez-Lopez, Benjamin Jones, Nicholas A. Isley, Ping Chen
  • TRICYCLIC PYRIDONES AND PYRIMIDONES
    Publication number: 20230203063
    Abstract: A compound of Formula (I) is provided: (I) where the variables are defined herein.
    Type: Application
    Filed: June 17, 2022
    Publication date: June 29, 2023
    Inventors: Jun FENG, Jean-Michel VERNIER, Marcos GONZALEZ-LOPEZ, Benjamin JONES, Nicholas A. ISLEY, Ping CHEN
  • TRICYCLIC PYRIDONES AND PYRIMIDONES
    Publication number: 20230159563
    Abstract: Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.
    Type: Application
    Filed: December 8, 2022
    Publication date: May 25, 2023
    Inventors: Jun Feng, Jean-Michel Vernier, Marcos Gonzalez-Lopez, Benjamin Jones, Nicholas A. Isley, Ping Chen
  • TRICYCLIC PYRIDONES AND PYRIMIDONES
    Publication number: 20230107642
    Abstract: Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 6, 2023
    Inventors: Jun FENG, Jean-Michel VERNIER, Marcos GONZALEZ-LOPEZ, Benjamin JONES, Nicholas A. ISLEY, Ping CHEN
  • Dihydrothieno[3,2-b]pyridine compounds
    Patent number: 11584755
    Abstract: Compounds are provided having Formula (I): wherein R, R1, Cyc and A have the meanings provided herein. The compounds have utility in the treatment of diseases, either alone or in combination with other agents.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: February 21, 2023
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Hilary Plake Beck, Leah Brigit Cleary, Michael Patrick Dillon, Marcos Gonzalez-Lopez, Luis Ruben P. Martinez, James Clifford Sutton, Jr.
  • AhR MODULATORS
    Publication number: 20230039955
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2e and R2d have the meanings provided in the specification.
    Type: Application
    Filed: June 29, 2022
    Publication date: February 9, 2023
    Inventors: Muzaffar ALAM, Hilary Plake BECK, Michael Patrick DILLON, Marcos GONZALEZ-LOPEZ, James Clifford SUTTON, JR.
  • Amido compounds as AhR modulators
    Patent number: 11548867
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: January 10, 2023
    Assignee: IDEA YA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Hilary Plake Beck, Michael Patrick Dillon, Marcos Gonzalez-Lopez, Alice Chen Rico, James Clifford Sutton, Jr.
  • Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR
    Patent number: 11530220
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formula: wherein the letters and symbols a, b, c, d, e, f, A, R1, X1, Ar1 and Ar2 have the meanings provided in the specification.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: December 20, 2022
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Hilary Plake Beck, Marcos Gonzalez-Lopez, James Clifford Sutton, Jr.
  • METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS
    Publication number: 20220340875
    Abstract: Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae: wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.
    Type: Application
    Filed: July 18, 2019
    Publication date: October 27, 2022
    Inventors: Muzaffar ALAM, Fred ASWAD, Hilary Plake BECK, Michael Patrick DILLON, Marcos GONZALEZ-LOPEZ, Yujiro HATA, Alice Chen RICO, James Clifford SUTTON, Jr.
  • AhR modulators
    Patent number: 11407764
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 9, 2022
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Hilary Plake Beck, Michael Patrick Dillon, Marcos Gonzalez-Lopez, James Clifford Sutton, Jr.
  • TRICYCLIC PYRIDONES AND PYRIMIDONES
    Publication number: 20220119409
    Abstract: A compound of Formula (I) is provided: where the variables are defined herein.
    Type: Application
    Filed: September 22, 2021
    Publication date: April 21, 2022
    Inventors: Jun FENG, Jean-Michel VERNIER, Marcos GONZALEZ-LOPEZ, Benjamin JONES, Nicholas A. ISLEY, Ping CHEN
  • METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING LACTAM COMPOUNDS
    Publication number: 20210254006
    Abstract: Provided are methods for expanding stem cells and/or lineage committed progenitor cells, at least in part, by using lactam compounds that antagonize AhR. The compounds are represented by formula (I): wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided below. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.
    Type: Application
    Filed: June 5, 2019
    Publication date: August 19, 2021
    Inventors: Muzaffar ALAM, Fred ASWAD, Hilary Plake BECK, Michael Patrick DILLON, Marcos GONZALEZ-LOPEZ, Yujiro HATA, James Clifford SUTTON, Jr.
  • AMIDO COMPOUNDS AS AhR MODULATORS
    Publication number: 20210115016
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.
    Type: Application
    Filed: July 18, 2018
    Publication date: April 22, 2021
    Inventors: Muzaffar ALAM, Hilary Plake BECK, Michael Patrick DILLON, Marcos GONZALEZ-LOPEZ, Alice Chen RICO, James Clifford SUTTON, Jr.
  • COMPOUNDS AND METHODS FOR THE MODULATION OF AHR
    Publication number: 20210079001
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formula: wherein the letters and symbols a, b, c, d, e, f, A, R1, X1, Ar1 and Ar2 have the meanings provided in the specification.
    Type: Application
    Filed: February 5, 2019
    Publication date: March 18, 2021
    Inventors: Hilary Plake BECK, Marcos GONZALEZ-LOPEZ, James Clifford SUTTON, JR.
  • AhR MODULATORS
    Publication number: 20210002297
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.
    Type: Application
    Filed: September 17, 2020
    Publication date: January 7, 2021
    Inventors: Muzaffar ALAM, Hilary Plake BECK, Michael Patrick DILLON, Marcos GONZALEZ-LOPEZ, James Clifford SUTTON, JR.
  • AhR modulators
    Patent number: 10815250
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: October 27, 2020
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Hilary Plake Beck, Michael Patrick Dillon, Marcos Gonzalez-Lopez, James Clifford Sutton, Jr.
  • AhR MODULATORS
    Publication number: 20190270754
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.
    Type: Application
    Filed: February 5, 2019
    Publication date: September 5, 2019
    Inventors: Muzaffar ALAM, Hilary Plake BECK, Michael Patrick DILLON, Marcos GONZALEZ-LOPEZ, James Clifford SUTTON, JR.
  • Spirocyclic EBI2 modulators
    Patent number: 10196369
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: February 5, 2019
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert Ardecky, Eduard A. Sergienko, Marcos Gonzalez-Lopez, Santhi Reddy Ganji, Jiwen Zou
  • EBI2 modulators
    Patent number: 9776979
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: October 3, 2017
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert Ardecky, Eduard A. Sergienko, Marcos Gonzalez-Lopez, Santhi Reddy Ganji, Jiwen Zou
  • EBI2 MODULATORS
    Publication number: 20160214951
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Application
    Filed: September 26, 2014
    Publication date: July 28, 2016
    Inventors: Anthony B. PINKERTON, Robert ARDECKY, Eduard A. SERGIENKO, Marcos GONZALEZ-LOPEZ, Santhi Reddy GANJI, Jiwen ZOU